Cargando…

IN MEMORIAM

Detalles Bibliográficos
Autor principal:	Huizinga, J.D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2007
Materias:	Interstitial Cells of Cajal Review Series
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909370/ http://dx.doi.org/10.1111/j.1582-4934.2005.tb00486.x

Ejemplares similares

Interstitial cells of Cajal in the urethra
por: Sergeant, G P, et al.
Publicado: (2006)

Relationships between neurokinin receptor-expressing interstitial cells of Cajal and tachykininergic nerves in the gut
por: Faussone-Pellegrini, Maria-Simonetta
Publicado: (2006)

Cajal : in memoriam.
Publicado: (1952)

Long-term outcome in biopsy-proven acute interstitial nephritis treated with steroids
por: Prendecki, Maria, et al.
Publicado: (2017)

Single-centre experience of granulomatous interstitial nephritis—time for a new approach?
por: Oliveira, Ben, et al.
Publicado: (2017)

Renal allograft granulomatous interstitial nephritis: observations of an uncommon injury pattern in 22 transplant recipients
por: Farris, Alton B., et al.
Publicado: (2017)

Sequencing of idiopathic pulmonary fibrosis-related genes reveals independent single gene associations
por: Coghlan, Meghan A, et al.
Publicado: (2014)

Ranking Self-reported Gastrointestinal Side Effects of Pharmacotherapy in Sarcoidosis
por: Drent, M., et al.
Publicado: (2020)

The Burden of Sarcoidosis Symptoms from a Patient Perspective
por: Voortman, M., et al.
Publicado: (2019)

Self-reported Gastrointestinal Side Effects of Antifibrotic Drugs in Dutch Idiopathic Pulmonary Fibrosis patients
por: Proesmans, V. L. J., et al.
Publicado: (2019)

Sarcoidosis and Work Participation: The Need to Develop a Disease-Specific Core Set for Assessment of Work Ability
por: Hendriks, C. M. R., et al.
Publicado: (2019)

Quantification of pulmonary perfusion in idiopathic pulmonary fibrosis with first pass dynamic contrast-enhanced perfusion MRI
por: Weatherley, Nicholas D, et al.
Publicado: (2021)

Dose modification and dose intensity during treatment with pirfenidone: analysis of pooled data from three multinational phase III trials
por: Nathan, Steven D, et al.
Publicado: (2018)

Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA(1)) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD)
por: Corte, Tamera J, et al.
Publicado: (2021)

Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF
por: Mercer, Paul F, et al.
Publicado: (2016)

Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials
por: Lancaster, Lisa, et al.
Publicado: (2016)

Derivation and validation of a simple multidimensional index incorporating exercise capacity parameters for survival prediction in idiopathic pulmonary fibrosis
por: Chandel, Abhimanyu, et al.
Publicado: (2023)

Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis
por: Nathan, Steven D, et al.
Publicado: (2016)

Reliability and responsiveness of the D12 and validity of its scores as a measure of dyspnoea severity in patients with rheumatoid arthritis-related interstitial lung disease
por: Swigris, Jeffrey J, et al.
Publicado: (2023)

Mediators of systemic sclerosis-associated interstitial lung disease (SSc-ILD): systematic review and meta-analyses
por: Fields, Aislin, et al.
Publicado: (2023)

‘It’s difficult, it’s life changing what happens to you’ patient perspective on life with chronic hypersensitivity pneumonitis: a qualitative study
por: Aronson, Kerri I, et al.
Publicado: (2019)

PGC1α repression in IPF fibroblasts drives a pathologic metabolic, secretory and fibrogenic state
por: Caporarello, Nunzia, et al.
Publicado: (2019)

Hospital-level variation in practices and outcomes for patients with severe acute exacerbations of idiopathic pulmonary fibrosis: a retrospective multicentre cohort study
por: Shankar, Divya A, et al.
Publicado: (2023)

Study design and rationale for the TETON phase 3, randomised, controlled clinical trials of inhaled treprostinil in the treatment of idiopathic pulmonary fibrosis
por: Nathan, Steven D, et al.
Publicado: (2022)

Randomised clinical trial of an early palliative care intervention (SUPPORT) for patients with idiopathic pulmonary fibrosis (IPF) and their caregivers: protocol and key design considerations
por: Lindell, Kathleen Oare, et al.
Publicado: (2018)

A qualitative study of informal caregivers’ perspectives on the effects of idiopathic pulmonary fibrosis
por: Belkin, Amanda, et al.
Publicado: (2014)

Needs, Perceptions and Education in Sarcoidosis: A Live Interactive Survey of Patients and Partners
por: Moor, C. C., et al.
Publicado: (2018)

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial
por: Maher, Toby M, et al.
Publicado: (2018)

Pretreatment of aged mice with retinoic acid supports alveolar regeneration via upregulation of reciprocal PDGFA signalling
por: Gokey, Jason J, et al.
Publicado: (2021)

The King’s Brief Interstitial Lung Disease (KBILD) questionnaire: an updated minimal clinically important difference
por: Sinha, Aish, et al.
Publicado: (2019)

Diagnoses and treatments for participants with interstitial lung abnormalities detected in the Yorkshire Lung Screening Trial
por: Upperton, Sara, et al.
Publicado: (2023)

Metabolic heterogeneity of idiopathic pulmonary fibrosis: a metabolomic study
por: Zhao, Yidan D, et al.
Publicado: (2017)

Analytic Morphomics in Myositis-Related Interstitial Lung Disease
por: O’Mahony, Alexander T., et al.
Publicado: (2023)

Time to diagnosis of idiopathic pulmonary fibrosis in the IPF-PRO Registry
por: Snyder, Laurie D, et al.
Publicado: (2020)

Central lung gene expression associates with myofibroblast features in idiopathic pulmonary fibrosis
por: Huang, Yong, et al.
Publicado: (2023)

Responsiveness and meaningful change thresholds of the Living with Pulmonary Fibrosis (L-PF) questionnaire Dyspnoea and Cough scores in patients with progressive fibrosing interstitial lung diseases
por: Swigris, Jeffrey J, et al.
Publicado: (2022)

Psychometric properties of the St George’s Respiratory Questionnaire in patients with idiopathic pulmonary fibrosis: insights from the INPULSIS trials
por: Swigris, Jeffrey J, et al.
Publicado: (2018)

Rationale for and design of the Idiopathic Pulmonary Fibrosis–PRospective Outcomes (IPF-PRO) registry
por: O'Brien, Emily C, et al.
Publicado: (2016)

Physical Inactivity in Pulmonary Sarcoidosis
por: Cho, Peter S. P., et al.
Publicado: (2019)

Cross-Atlantic modification and validation of the A Tool to Assess Quality of Life in Idiopathic Pulmonary Fibrosis (ATAQ-IPF-cA)
por: Yorke, Janelle, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_p2evv29gna26dvnlggilah1fkd